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objectives. This investigation sought to determine whether 
endothelium-derived nitric oxide contributes to hypoxia-induced 
systemic vasodilation and pulmonay vasoconstriction in humans. 
Buck.gr~~I. Endothelium-derived nitric oxide contributes to 
basal systemic and pulmonary vascular resistance. During by- 
poxia, systemic vasodilation and polmonary vasoconstriction oc- 
cur. There are some data indicating that endotbelium-derived 
nitric oxide mediates changes in vascular resistance during 
hypoxia, but much of it is contradictory, and none bas been 
derived from normai humans. 
Methods. The hemodynamis effesbs of N”-monomethyl-L- 
arginine (L-NMMA), a nitric oxide synthase inhibitor, were stud- 
ied in healthy vohmteers under normoxic and hypoxic conditions. 
A Swan-Ganz catheter and radial artery cannula were inserted to 
measure right atrial, pulmonary artery, pulmonary capillary 
wedge and systemic blood pressures. Cardiac output was mea- 
sured by thermodilntion. Systemic vascular resistance and pul- 
monary vascular resistance were calenlakd. The pharmacokinet- 
its of L-NMMA (3Og mg intravenously) was studied during 
normoxia in six subjects. Hypoxia was induced in eight subjects 
- 
Hypoxia elicits a complex set of physiologic responses that 
regulate vasomotor tone. These effects differ in the systemic 
and pulmonary circulations. Hypoxia causes vasodilation of 
systemic arterioles and vasoconstriction in the pulmonary 
circulation. Each of these responses appears to be protective: 
One results in a greater blood suppiy to systemic organs to 
meet the metabolic demand of hypoxic tissue, whereas the 
other minimizes perfusion to poorly oxygenated portions of the 
lung, thereby improving ventilation/perfusion matching to re- 
store arterial oxygenation. 
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who inspired a mixture of nitrogen and oxygen through a gas 
blender adjusted to reduce the partial pressure of oxygen fkom 
(mean 5~ SE) 98 -+ 4 to 48 5~ 1 mm Hg. 
Resuk During normoxia, L-NMMA increased systemic vascu- 
lar resistance from P,PDtl -C 74 to 1,705 +- 87 dynesscm-’ and 
increased pulmonary vascular resisfance from 60 +- 5 to 1.15 -c 9 
dynes-scmq5 (p C 0.01 for each). Peak effects occurred within 
10 min of L-NMMA administralion. Acute hypoxia alone de- 
creased systemic vascular resistance from 1,209 2 78 to 992 a 58 
dynesscmW5 (p % 0.05) and increased pulmonary vascular resis- 
tance fmm 92 9~ 11 to 136 * 4 dynessTm+ (p 5 0.01). Wile 
bypoxic conditions were maintained, infusion of L-IWM.4 in- 
creased systemic vascular resistance (to 1,496 k 97 dynes-s%m-‘, 
p 5 0.01.) and increased pulmonary vascular resistance further (to 
217 k 25 dllnkes-Vcm-s, p 5 0.01). 
Cunclusions Endothelium-derived nitric oxide contributes to 
systemic vasodilation and serves as a counterregulatory mecba- 
nism to attenuate pulmonary vasoconslriction during acute hy- 
poxia in healthy human subjects, 
(J Am COM Canliol I996;zs:s91*~ 6) 
Endotheiium-de.rived nitric oxide is constitutively released 
by the endothelium and plays a critical role in regulating basal 
tone in both the systemic and pulmonary vascular beds (l-4). 
When studied under normoxic conditions, nitric oxide synthase 
antagonists, such as fl-monomethyLt-aginine CL-NhrlMA), 
increase systemic and pulmonary vascular resistance in exper- 
imentai animals and healthy h~rtrnlm subjects (3?4). Although 
there arc some data indicating that endotheiium-derived nitric 
oxide mediates changes in vascular resistance during hypoxia, 
much of it is contradictory, and none have been derived from 
normal humans (5-19j. Accordingly, we conducted an experi- 
ment in normal human volunteers to determine the c#ects of 
acute hypoxia on ihc systemic and pulmonary vasculature and, 
specifically, to assess the role of endothciium-derived nitric 
oxide as a mediator of these vasomotor responses. 
Subjects. The study included 12 normal volunteers f-C men, 
7 women; mean [YD] age 34 rt: 6 years! ranged 23 to 431, 
Normalcv was determined before enrollment by history, phys- 
ical exanknation and laboratory analyses. Subjects with vasclj- 
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lar risk factors, such as diabetes, hypertension and dyslipide- 
rnia, as well as those with evidence of cardiac, renal, hepatic or 
hamatologic abnormalities were excluded. Only one subject 
had a history of cigarette use. All had low density lipoprotein 
cholesterol levels less than the 50th percentile for age and 
gender. No subject was taking any medication. The study was 
approved by the Human Research Ccmmittee of the Brigham 
and Women’s Hospital, and all patients provided written 
informed consent before the start of the study. 
Wemorlynamic measurements. Each subject was studied in 
a 23” temperature-controlled room in the postabsorptive state. 
Caffeine, aspirin and nonsteroidal inflammatory agents were 
all prohibited within 12 h of the study. Under local anestb, a 
and sterile conditions, a 20”gauge polyethylene catheter was 
inserted into the right radial artery of each subject for systemic 
blood pressure (BP) monitoring and arterial blood gas deter- 
minations. An 8SF Cordis sheath was placed percutaneously 
into the right internal jugular vein. An 8F five-lumen thermodi- 
lution catheter (Abbott Critical Care Systems) was then ad- 
vanced undei continuous pressure monitoring into the pulmo- 
nary arteq to measure pulmonary capillary wedge pressure, 
pulmonary artery pressure (PAP) and right atria1 pressure 
(RAP). The catheters were attached to Gourd P23 transducers. 
The phlebostatic axis was estimated to be 5 cm vertically 
beneath the sternal angle of Lewis. All hemodynamic measure- 
ments were recorded on a Gould 4600 Physiologic Recorder. 
Heart rate was calculated from the mean of 10 consecutive RR 
intervals from an electrocardiographic signal. Cardiac output 
(CO) was measured by thermodilution using lo-ml boluses of 
room temperature normal saline as the injectate. A minimum 
of three cardiac output measurements were made at each point 
and the results averaged. Systemic vascular resistance was 
calculated as [(Mean BP - RAP)/CQ] X 80 and pulmonary 
vascular resistance as [(Mean PAP - PCWP)/CO] X 80. Both 
were expressed as dynesscm-“, 
Induction of hypoxia. Study participants breathed a 
nitrogen-oxygen mixture through an air-oxygen blender (Pu- 
ritan Bennett Corp.), with nitrogen connected to the air inlet 
of the blender and ~~~11 source oxygen to the oxygen inlet. By 
changing the proportion of the two gases through the blender 
unit, the fraction of inspired oxygen (Fro,) ddivered to the 
study subject could be precisely regulated. The blender was 
connected to a gas-powered demand valve in series with a 
non-rebreathing valve (Life Support Products, Inc.). The 
subject breathed through a sealed mouthpiece (Puritan Bcn- 
nett Corp.). A nose clip was placed to ensure that no air was 
entrained through the nose. 
Real-time measurements of the inspired oxygen content 
was accomplished using a digital oxygen monitor (Catalyst 
Research) attached to the inlet of the non-rebreathing valve. 
Blood oxygen saturation was approximated by finger probe 
oximetry (Ghmeda) and confirmed by arterial blood gas anal- 
ysis of the partial pressure of oxygen (PO& Basal oxygen 
delivery was 21% oxygen An Fro, of between 12.8% and 
34.5% was required to create hypoxic conditions, approximat- 
ing a PO, of 50 mm Hg and corresponding to an oxygen 
saturation of 84%. 
Experimental protocols. All subjects rested at least 20 min 
after placement of the catheters, mouthpiece and nose clip 
before data collection. The vascular research laboratory was 
kept quiet, and the lights were dimmed. Two separate exper- 
imental protocols were conducted. 
Protocol 1. The pharmacokinetics of the nitric oxide syn- 
thase antagonist L-NMM4 was investigated under normoxic 
conditions in six subjects to determine the timing of its 
maximal efTect and the duration of action. Normoxic condi- 
tions were maintained the entire time; nonetheless, the face 
mask apparatus was still used to match the conditions of the 
hypoxia experiment (described later). Baseline hemodynamic 
measurements were repeated over a 30-min period, and sta- 
bility was ensured. Thereafter, L-NMMA (Ctinolfa, Switzer- 
land) 300 mg (-4 mg/kg body weight) was infused through the 
side port of the Cordis sheath over 4 min. Hemodynamic 
measurements were taken every 10 min for the next 1 h. The 
dose of L-NMMA was comparable to that used safely in a 
previous study (4). 
Protocol 2. The role of endothelium-derived nitric oxide in 
regulating systemic and pulmonary vascular resistance under 
hypoxic conditions w-as investigated. In eight subjects, includ- 
ing two from the first protocol, baseline hemodynamic mea- 
surements were initially taken under normoxic conditions for 
-30 min. Thereafter, hypoxia was induced as previously de- 
scribed to reduce the PO, to ,-50 mm Hg. Hemodynamic 
measurements and blood gas analyses were repeated. Then, 
while maintaining hypoxia, L-NMMA (300 mg) was infused 
through the sheath. Hemodynamic measurements were ob- 
mined immediately after the completion of the L-NMMA 
infusion because the pharmacokinetics studies previously de- 
scribed found that the peak effect of L-NMMA on systemic and 
pulmonary vascular resistance occurred promptly and gradu- 
ally dissipated after 10 min (see Results). lSLood gas analysis 
was performed to ensure that hypo.xic conditions had reasined 
stable. 
Statistical analysis. All results are presented as mean 
value 2 SE. The effect of L-NMMA on the hemodynamic 
variables in Protocol 1 was analyzed by one-way analysis of 
variance with repeated naeasures. Post hoc comparisons be- 
tween baseline and the peak hemodynamic effect of L-NMMA 
were made using paired two-tailed r tests. For Protocol 2, the 
comparisons between normoxia and hypoxia. and those be- 
tween hypoxia alone and hypoxia after L-NMMA admlnistra- 
tion, were made using paired two-tailed t tests. Statistical 
significance was accepted at the 95% confidence level (p < 
0.05). 
Iteesults 
Pharnucokinetics of L~NMMA. In the normoxic control 
experiments, the peak effect of L-NMMA on blood pressure 
and systemic vascular resistance occurred within 1 min of 
completion of the L-NMMA infusion (Fig. 1). A gradual 
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Figwe 1. Ekct of L-NM~~A (303 n;g intrave- 
nously) on systemic vascular resistance (SVR) 
and pulmonary vascular resistance (PVR). 
I,-NMMA increases systemic vascular resistcncc 
signilicantly (p c 0.001 by ANOVA), with peak 
effect occurring within 1 min of drug adminis- 
tration. I.-NMMA ako increased pulmanaq 
vascular esistance significantly (p < 0.001 by 
ANOVA), with peak effect occurring within 
10 ruin of drug administration. Results are 
mean value 5 SE. BASE = baseline; d.sc? = 
dynesscm-- j. 
diminution of its effects occurred over the next hour, At peak 
effect, L-NMMA increased mean blood pressure by 14% (p 5 
0.01) and systemic vascular resistance by 540/o, (p 5 0.01) 
(Table 1). Cardiac output decreased by 28% (p 5 0.01). 
Forty-two percent of the systemic vasoconstricting effect of 
L-NMMA was lost by 20 min and 76% by 1 h. The trend was 
similar for pulmonary vascular resistance. L-NMMA increased 
mean pulmonary artery pressure by 40% (p < 0.05) and 
pulmonary vascular resistance by 92% (p 5 0.01); the maximal 
effect occurred 10 mm after completion of the infusion. 
Forty-three percent of tht pulmonary vasoconstricting effect of 
I.-NMMA was lost by 1 h. 
Effect nf hypoxia on systemic and pulmonary hemdym+m- 
its. Hypoxia was induced by lowering the inspired oxygen 
from 21.0% 2 0.1% to 13.3% 5 0.2% (p < O.OO!). This 
resulted in a deLrease In Pea from 98 rt 4 to 48 rt 1 mm Hg 
(p < O.OtB). Mild hyperventilation was proked by the 
hypoxic stimulus, evidenced by a decrease in the partial 
pressure of carbon dioxide from 42 t 1 to 38 It 1 mm Hg (p < 
0.01) and an increase in the pH from 7.38 t 0.01 to 7.42 5 0.01 
(j.7 *< 0.01). 
Hypoxia caused substantial and distinct hemodynamic 
changes in the systemic and pulmonary circulations (Table 2). 
Systemic vascular resistance decreased 18% (p c: 0.05 vs. 
Table 1. Effect of h”‘-Monomcthyl-i;Arginine on Ncmodgnamic 
Measurements During Normoxin ------ - -. 
Basr:li11c (mesn 7. SE) is-NMMA (mean 2 SE) 
-~--__I---~ -l-__l” 
SW (dynewcm+) 1,108 2 74 1.705 ?1 lw 
BP (mm Hg) 88 I 5 1aO54* 
CO (lknimin) 6.32 z 0.38 4.57 t 0.28” 
PVR (dyncsscm .‘) 6ri ‘c 5 11s 2: 9* 
PAP (mm Hg) IO” 2 14 ” I? 
YCWP (mm Ng] si-I ‘7 2 1 
RAP (mm Hg) 221 421 
IIK (beatsimin) gj 2 5 52 r JJ 
I - 
*p 5 0.01 and ip < 0.05, baseline conditions wcus peak hemodynamic 
effect for each mcasurcmcnt after completion of ‘~~-fltonomethyl-rrarginine 
(L-NMMA) infusion. BP = blood prcssurc; CD = cardiac output: HR = heart 
rate; PAP = pulmonary artery pressure; PCW = pulmonary capillary wed& 
pressurtr; PVR = pulmonary vascular rcsistancc; RAP = right atrial pressure; 
SVK - systemic vascular rcsistancc. 
-. 
normoxia), reflecting a 27% increase in cardiac output (p 5 
0.05) a small but statistically insignificant decrease in mean 
blood pressure and a significant decrease in right atria1 pres- 
sure (p C= tki5) (Fig. 2). In contrast, pulmonary vascular 
resistance increased 46% (p < 0.01) reflecting the increase in 
pulmonary artery pressure (p 5 0.05:) and decrease in pulmo- 
nary capillary wedge pressure (p CC 0.05) (i.e., the increased 
transpulmonary pressure gradient) (Fig. 3). 
Effect of I,-NMMA on hypoxic responses. While maintain- 
ing stable hypoxk conditions (Paz from 4X 2 1 to 47 5 
I mm Hg, p = NS), intravenous infusion of L-NM&I in- 
creased mean b+jod pressure 16% (p < 0.01 vs. baseline 
hypoxia) and deceased cardiac output 24% (p 5 0.01) (Fig. 2, 
Table 2). This rc~ulted in a 51% increase in systemic vascular 
resistance (p < O.O!), reversing the initial hypoxic-induced 
vasodilation. Relevant to the pulmonary circulation. L-NMMA 
admin&ation ~rir: hypoxra increased puln:orurq~ artery 
pressure 27% (p I”r U.tIj)* causing 3 furiher 60% inizase in 
pulnronary vascuiar resistance (p ‘: f).Oi) (Fig. 3. Table 2). 
The salient findings resulting from the present skrdy are 
that I) acute hypoxia causes systemic vasodihnion and pui- 
monarv vasoconstriction in healthy human subjects; 2) 
Normcsia 
(mean _+ SE) 
sVR (dynewcm-‘) 
BP (mm Hg) 
CO (liter~/min) 
PVR (dyncswm’-‘) 
PAP (mm Hg) 
PCWP (mm F&j 
RAP (mm Hg) 
HR (bcatsi’min) 
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BP SWR 
CmmHg) (de+) 
Figure 2. Effect of hypoxia alone (hatched columns) and hypoxia after 
L-NMMA administration (solid columns) on mean blood pressure 
(BP) and systemic vascular resista:ice (SVR). Open columns = 
normoxia. Results are mean value 2 SE. *p ‘1 0.05. **p c G.01.. 
d*s,c? = dyne%scme5. 
endothelium-derived nitric oxide is responsible, at least in part, 
for the systemic vasodilation that occurs during hypoxia; and 3) 
endothelium-derived nitric oxide is an important counterregu- 
iatory mechanism to attenuate hypoxia-induced pulmonary 
vasoconstriction, 
Hypoxia-mediated vascular responses. The observation 
that hypoxia causes peripheral vasodilation is not new and has 
been reported by others in experimental models as well as in 
humans. In a series of studies, Guyton and colleagues (20-23) 
found that direct infusion of hypoxic blood into canine limbs or 
isolated arterial segments caused vasodiiation. Forearm vaso- 
dilation has been observed in humans subjected to hypoxic 
conditions comparable to those described in the present 
experiment (24-26). Hypoxia-induced changes in systemic 
vascular resistance also include a vasoconstrictive component, 
mediated by chemoreceptor activation of the sympathetic 
nervous system, as well as a vasodilator component, presum- 
ably caused by local release of vasoactive substances (27-31). 
Hypoxia causes systemic vasodilation in chemoreceptor- 
denervaeed dogs and reduces blood pressure in humans who 
have undergone resection of the carotid bodies (27,23). 
Hypoxia-induced p&nonary vasoconstriction was first shown 
in 1946 by von Euler and Liljestraad (32), studying feline 
pulmonary arteries, and reported in humans by Motley et al. 
(33) in 1947. These observations hs;c been confirmed subse- 
quently in numerous basic and clinical investigations (for 
review, see Voelkel [%I), 
In our study, hypoxia decr$:ased systemic vascu!ar resistance 
and increased pulmonary vascular resistance. Cardiac output 
increased, presumably as a conseT-ence of reduced afterload, 
as well as from the positive inotropic and chronotropic effects 
of chemoreceptor-mediated zctivation of sympathetic effer- 
ents. These findings are co!,sistent with observations made 
previously by others, a: cited previously, and establish a 
framework on which we examined the contribution of 
endothelium-derived nitric oxide. 
Pharntacalsgic effects of L-NMMA. A single dose of 
L-FUPUVU (300 mg intravenously) caused a prompt increase in 
PAP PWR 
ImmHg) (d.s&) 
Figure 3. Effect of hypoxia alone and hypoxia after L-NMMA admin- 
istration on mean pui;;lonary artery pressure (PAP) and pulmonary 
vascular esistance (PVK). Results_ are mean value + SE. *p < 0.05. 
**p < 0.01. d*sc-’ : dynesscm-“. Symbols as in Figure 2. 
systemic vascular resistance. L-NMMA also increased blcod 
pressure and decreased cardiac output. These observations are 
similar to those from our previous study in which we adminis- 
tered L-NMMA, through a dose-titration schedule, to normal 
volunteers (4). In that study, $asma nitric oxide levels were 
measured and decreased by 65% after L-NMMA administra- 
tion. On the basis of each of these studies, we can conclude 
that endothelium-derived nitric oxide contributes to basal 
systemic vascular tone. The decline in cardiac output most 
likely results from increased afterload as well as from 
baroreflex-mediated withdrawal of sympathetic efferent activ- 
ity. It is unlikely that L-NMMA has a direct negative inotropic 
effect because nitric oxide synthase antagonists increase con- 
tractility in isolated myocytes in vitro and autonomically den- 
ervated dogs in vivo (3.536). I,-NMMA also increased pulmo- 
nary vascular resistance, an effect that peaked 10 min after 
drug administration. Pulmonary vasoconstriction had also oc- 
curred in our previous study, indicating that endothelium- 
derived nitric oxide contributes to pulmonary vascular tone 
under normoxic conditions (4). In the current study, we 
assessed the time course of the hemodynamic effects of 
L-NMMA to plan the hypoxia experiments. We determined 
that measurements after L-NMMA administration had to be 
made promptly because of its short half-life, while patients 
remained hypoxic. 
Contribution sf endobheiium-derived tiiric oxide to sys- 
temic vasudilation during hypoxia. Evidence derived from 
experimental models implicates the endothelium as a critical 
source of a vasodilator ,ubstance during hypoxia (X2,13,37- 
40). Hypoxia-induced relaxation of rabbit aortic and femoral 
artery segments is attenuated by endothelial denudation or 
when hemoglobin is present to quench nitric: oxide (12,37). 
These findings are consistent with bioassay experiments, in 
which perfusate from hypoxic cultured bovine endothelial cells 
or from endothelium-intact rabbit aortic segments dilate de- 
n&d arterial segments (37). Dilation of the denuded seg- 
ments is blocked by pretreatment with hemoglobin. Also, 
hypoxia causes coronary vasodilation and increases the cyclic 
guanosine monophosphate content in guine$ pig hearts ex$vd ,’ 
(13). These effects are inhibit& in part, ‘by the nitric oxide ; 
.; ’ ; : ; ,,,_:; 
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synthase antagonist N”-methyl-- arginine, further underscor- 
ing the contribution of nitric o&de as a mediator of hypoxia- 
induced vasodilation. Furthermore, when studied in rats in 
vivo, @-nitro-L-arginine substantially attenuates the hypoten- 
sive response to hypoxia (39). Other endotheiium-derived 
vasodiiators, such as prostacyclin, may contribute also to 
hypoxia-induced vasodiiatfon (13,37,38). 
The data fro:0 our study indicate that endothelium-derived 
nitric oxide is present and contributes to systemic vasodilation 
during acute hypoxia in humans, as evidenced by the increase 
in systemic vascular resistance that occurs when L-NMMA is 
administered to healthy subjects under hypoxic conditions. 
From these experiments, it is not possible to determine 
whether hypoxia actually increases the amount of nitric oxide 
in the systemic circulation because the degree of systemic 
vasoconstriction was similar when L-NMMA was administered 
under normoxic (Protocol 1) or hypoxic (Protocol 2) condi- 
tions. The short duration of action of L-NMMA after bolus 
administration precluded a direct comparison be!ween nor- 
moxia and hypoxia in the same .&jects. However, we recently 
completed a study that addressed this possibility. L-NMMA 
was infused continuously into the brachial artery of normal 
volunteers. The forearm vasoconstrictive response to L- 
NMMA was significantly greater under hypoxic than normoxic 
conditions, indicating that increased availability of nitric oxide 
accounts for a significant component of hypoxia-induced fore- 
arm vasodilation (40). 
Endothelium-derived nitric oxide counterregulates hypxic 
pdmonary vasoconstriction. Published reports dispute whether 
hypoxia results in increased (14-19,41,42) or decreased 
(10,11,43-46) release of nitric oxide from the pulmonary endo- 
thelium. Distinctions become apparent when one considers the 
experimental preparation and the severity and chronic@ of 
hypoxia. Endotheiium-dependent relaxation is impaired in the 
rings of rat (ll), rabbit (46) and porcine (10) pulmonary arteries 
exposed to severe hypoxia in vitro. The expression of nitric oxide 
synthase may be reduced with severe hypoxia, thereby limiting 
synthesis of nitric oxide (47). Indeed, in other experimental 
models of acute and less severe hypoxia, including exvivo rat lung 
preparations (14-16,42), and in viva experiments using newborn 
iambs (43), rabbits (17,B) and dogs (19), endothelium-derived 
nitric oxide is present and attenuates hypoxic pulmonary vasocon- 
striction. Another important difference between in vitro experi- 
ments and ex vivo and in vivo preparations is the size of the 
vessels being studied. The latter two assess the pulmonary micro- 
circulation and as such may be more relevant to hypoxia-induced 
pulmonary vasoconstriction. Several studies indicate that there is 
decreased availability of nitric oxide during chronic states of 
hypoxia, For example, chronic hypoxia causes progressive loss of 
endothelium-dependent relaxation in the isolated rat lung prep 
arat& (43). Endothelium-dependent relaxation is also less in 
pulmbnary artery rings excised during transplantation from pa- 
tiei& $Gth chroni? ‘hypox$i se&mc@ry to obstructive’ludg disease 
than jin , rip@ from: n+@ic st@jC&s whost: lungs bad been 
re%d b@u$ ‘“fi ~r$o’ i44,. Chronic&y of &qxia might ! ‘ ,, 
influence vascular reactivity, particularly if morphologic changes 
in the endotheiium have occurred (4). 
In our study, L-NMMA increased pulmonary vascular resis- 
tance during hypoxia. This finding indicates that endothelium- 
derived nitric oxide is present in the pulmonary circulation of 
healthy humans to counterregulate acute hypoxia-induced 
pulmonaryvasoconstriction. These findings do not enable us to 
determine whether the bioavaiiabiiity of nitric oxide is affected 
by increased synthesis or decreased degradation. Because 
expression of eonstitutive nitric oxide synthase is inhibited with 
severe hypoxia, it is not likely that nitric oxide synthase was 
increased, even under less hypoxic in vivo conditions (47). It is 
not known whether the level of hypoxia achieved in vivo 
reduces the concentration of superoxide radicals and thereby 
decreases inactivation of nitric oxide (48-50). 
Potential mechanisms of pulmonary vasocanstriction. We 
can discount reduced endothelium-derived nitric oxide as the 
cause of pulmonary vasoconstriction during acute hypoxia. 
Prostacyciin, like nitric oxide, may attenuate hypoxia-induced 
pulmonary vasoconstriction (18). Other candidate mechanisms 
include increased endothelin and histamine levels, increased 
alpha-adrenergic activity and inhibition of adenosine 
triphosphate-sensitive potassium (KATP) channels. Endotherm 
release increases during hypoxia (3); yet, exogenously infused 
endothelin causes minimal change or even vasodilation in the 
pulmonary circulation (51,52). In animal models, histamine 
receptor antagonists inhibit hypoxia-induced pulmonary vaso- 
constriction (53). Observations that hypoxia-induced puhno- 
nary vasoconstriction can occur in ex vivo lung preparations 
and in transplanted lungs in vivo (14,15,43,54) argue against a 
role for sympathetic activation. The findings that hypoxia 
causes depolarization of pulmonary artery smooth muscle cells 
and that KATP inhibition constricts the pulmonary circulation 
in fetal iambs are potentially exciting, albeit still circumstantial, 
evidence of a important role for this channel in mediating 
hypoxic vasomotor tone (55,56). 
Conclusions. Acute hypoxia causes systemic vasodiiation 
and pulmonary vasoconstriction in healthy human subjects. We 
found that endothelium-derived nitric oxide modulated both of 
these processes, extending observations made in expcrimentai 
animal models. In the pulmonary circulation, endotheiium- 
derived nitric oxide serves as a counterregulatory mechanism 
to attenuate pulmonary vasoconstriction, whereas in the sys- 
temic circulation, it is present during acute hypoxia and 
codtributes to the resulting systemic vasodiiation. 
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